Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — September 2025

Genmab — September 2025

Planlagt Fastgjort Låst Flyttet Genmab
283 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • R Offline
    R Offline
    Raun
    wrote on sidst redigeret af
    #244

    Det giver jo god mening 🙂

    1 Reply Last reply
    0
    • R Offline
      R Offline
      Raun
      wrote on sidst redigeret af
      #245

      Ovenstående som svar på E L kl. 20.11

      1 Reply Last reply
      0
      • R Offline
        R Offline
        Raun
        wrote on sidst redigeret af
        #246

        sorry kl. 20.06 🙂

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #247

          😉

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #248

            Leerink Partners raised its price target on Genmab A/S (NASDAQ:GMAB) to $34.00 from $32.00 on Monday, while maintaining an Outperform rating following the company’s proposed acquisition of Merus https://www.investing.com/news/analyst-ratings/leerink-partners-raises-genmab-stock-price-target-on-merus-acquisition-93CH-4261527

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #249

              New trial - Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL) (CLEAR) https://clinicaltrials.gov/study/NCT07197307

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #250

                Spændende forsøg med Zylonta fra ADC Therapeutics og Epco. Zylonta viser gode takter med Columvi https://ir.adctherapeutics.com/press-releases/press-release-details/2025/ADC-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Operational-Update/default.aspx Meddelelsen viser også, at ADC kæmper med økonomien.

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #251

                  US tog pænt mod opkøbet. Lukkekurs svarer til 1867.

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    gentogen
                    wrote on sidst redigeret af
                    #252

                    Volume 4,995,630

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #253

                      Tegner lovende.

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #254

                        Godmorgen 🙂

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          ProinvestorNEWS
                          wrote on sidst redigeret af
                          #255

                          Genmab får løftet kursmålet af Cowen med 36 pct. efter kæmpeopkøb https://proinvestor.com/investornyt/1366477/genmab-far-loftet-kursmalet-af-cowen-med-36-pct-efter-kaempeopkob

                          1 Reply Last reply
                          0
                          • royalR Offline
                            royalR Offline
                            royal
                            wrote on sidst redigeret af
                            #256

                            På et tidspunkt troede/håbede jeg at Jans speedsnak om KYSO og andre fortræffeligheder som skulle komme var en slags salgstale for JnJ, men han mener det. 🙂

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              ProinvestorNEWS
                              wrote on sidst redigeret af
                              #257

                              Genmabs kursmål løftes 6 pct. hos Leerink efter milliardopkøb https://proinvestor.com/investornyt/1366476/genmabs-kursmal-laeftes-6-pct-hos-leerink-efter-milliardopkob

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                ProinvestorNEWS
                                wrote on sidst redigeret af
                                #258

                                Tirsdagens danske avisuddrag med Genmab, Novo og Søstrene Grene https://proinvestor.com/investornyt/1366486/tirsdagens-danske-avisuddrag-med-genmab-novo-og-sostrene-grene

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #259

                                  Cowen likes 2015 lol https://www.sydinvest.dk/nyheder/genmabcowen-saenker-kursmaal-til-2015-kr-fra-2196-kr

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #260

                                    'Reporting from Bloomberg News on Sunday revealed that several pharmas have been courting the cancer biotech in recent weeks, and that Genmab appeared to have been leading the pack.' https://www.biospace.com/business/genmab-buys-rising-cancer-star-merus-for-8b

                                    1 Reply Last reply
                                    0
                                    • L Offline
                                      L Offline
                                      lahn1
                                      wrote on sidst redigeret af
                                      #261

                                      Det er flot hvis Gmab igen har været først ud og har købt Merus for næsen af flere andre interesserede.

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #262

                                        (just a small nuance, the transaction is not final yet; they have not yet bought it. theoretically it could still fail, even another company bidding at a higher price.)

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #263

                                          the press release for the Mim8 news Goose3 referred to yesterday
                                          https://www.prnewswire.com/news-releases/novo-nordisk-submits-biologics-license-application-bla-to-fda-for-mim8-an-investigational-prophylaxis-treatment-for-people-living-with-hemophilia-a-with-or-without-inhibitors-302568838.html

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper